Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

Third-Line Treatment in Refractory CRC

February 26th 2018

Immunotherapy Options in Refractory CRC

February 26th 2018

Supportive Care in Metastatic CRC

February 26th 2018

Maintenance and Second-Line Decisions in CRC

February 26th 2018

Frontline Antibody Selection in Metastatic CRC

February 26th 2018

Left- Versus Right-Sided Tumors in CRC

February 26th 2018

Importance of HER2 Expression in CRC

February 26th 2018

Role of Molecular Testing in CRC Management

February 26th 2018

Early-Onset CRC: What Do We Know?

February 26th 2018

Treating Liver or Peritoneal Metastases in CRC

February 26th 2018

Managing Patients After Adjuvant Therapy

February 26th 2018

Duration of Adjuvant Therapy: CRC Subsets

February 26th 2018

Deciding on Adjuvant Therapy in CRC

February 26th 2018

Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis

February 6th 2018

Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).

Dr. Lagunes on Potential Combinations in the Treatment of Patients With NETs

February 3rd 2018

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials and recent approvals that will shape the standard of care in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Abou-Alfa on Sequencing Agents in the Treatment of Patients With HCC

February 3rd 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.

Keeping a Tight Rein on Unnecessary Expenditures in Oncology Practice

January 27th 2018

Doctors from Intermountain Healthcare decided to see if they could improve outcomes of patients placed on expensive machines.

FDA Approves Lutathera for GEP-NETs

January 26th 2018

The FDA has approved Lutathera for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Proving "Noninferiority" May Become Another Challenge in Oncology Studies

January 17th 2018

Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.

Dr. Bauml Discusses Biomarkers in Head and Neck Cancer

January 11th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.